<DOC>
	<DOCNO>NCT00077636</DOCNO>
	<brief_summary>This study evaluate efficacy safety different duration treatment PEGASYS combine ribavirin patient CHC genotype 2 3 infection never previously receive interferon ( IFN ) therapy . The anticipated time study treatment 3-12 month target sample size 500+ individual .</brief_summary>
	<brief_title>ACCELERATE Study - A Study PEGASYS ( Peginterferon Alfa-2a ( 40KD ) ) Combination With COPEGUS ( Ribavirin ) Interferon-Naive Patients With Chronic Hepatitis C ( CHC ) Infection .</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>patient &gt; =18 year age ; CHC infection ( genotype 2 3 ) ; liver biopsy ( &lt; 24 calendar month first dose ) , result consistent CHC infection ; use 2 form contraception study 6 month study men woman . woman pregnant breastfeeding ; male partner woman pregnant ; condition associate decompensated liver disease ; form liver disease , include liver cancer ; human immunodeficiency virus infection ; previous treatment IFN , pegylated IFN , ribavirin , viramidine , levovirin , amantadine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>